Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769505 | 1.00 | CRBN (0.36) | CRBNLMNATSHRPARP1AR | |
| SCHEMBL20769510 | 1.00 | CRBN (0.36) | CRBNLMNATSHRPARP1AR | |
| SCHEMBL13322347 | 0.77 | LMNA (0.37) | LMNATSHRPARP1ARNR3C1 | |
| SCHEMBL22392284 | 0.74 | CRBN (0.35) | CRBN | |
| SCHEMBL22402108 | 0.74 | CRBN (0.35) | CRBN | |
| SCHEMBL13322346 | 0.71 | NPSR1 (0.38) | LMNATSHRPARP1ARNR3C1 | |
| SCHEMBL22392234 | 0.69 | CRBN (0.32) | CRBN | |
| SCHEMBL22702293 | 0.69 | CRBN (0.44) | CRBNLMNATSHR | |
| SCHEMBL1188908 | 0.69 | CRBN (0.44) | CRBNLMNATSHR | |
| SCHEMBL3668437 | 0.69 | CRBN (0.44) | CRBNLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| CN-111051316-B | Pentacyclic compounds | 卫材R&D管理有限公司 | 2022-05-31 | — | — | CN | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3680243-B1 | PENTACYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| EP-3680243-B1 | PENTACYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| EP-3680243-A1 | PENTACYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-3680243-A1 | PENTACYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-10239889-B1 | Pentacyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| US-10239889-B1 | Pentacyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| WO-2019049869-A1 | PENTACYCLIC COMPOUND | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2019-03-14 | — | — | WO | disclosed |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239889-B1 | Pentacyclic compound | CYP2B6, CYP11B2, CYP3A5 | CRBN 3811/4885LMNA 3514/4885TSHR 4104/4885 |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | CYP2B6, CYP3A5, CYP4A11 | CRBN 4134/4885LMNA 3926/4885TSHR 3626/4885 |
| US-11358972-B2 | Pentacyclic heterocycles | CYP2C19, CYP2C18, XDH | CRBN 2946/4885LMNA 2306/4885TSHR 2533/4885 |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | CYP2C19, CYP2C18, XDH | CRBN 2946/4885LMNA 2306/4885TSHR 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.